07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Anaconda Pharma, Biota Pharmaceuticals deal

Biota completed its acquisition of Anaconda for $8 million in cash and 3.5 million Biota shares, valued at $7.5 million based on Biota’s close of $2.15 on June 2, before the deal closed (see BioCentury,...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Company News

Anaconda Pharma, Biota Pharmaceuticals deal

Biota is acquiring Anaconda for $8 million in cash and 3.5 million Biota shares, valued at $8.7 million based on Biota’s close of $2.48 on Feb. 25, before the deal was announced. Anaconda shareholders are...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

AP611074: Phase IIa data

A double-blind, placebo-controlled, Phase IIa trial in 24 condyloma patients showed that twice-daily AP611074 5% topical gel for 6 weeks was safe with no patient drop-outs or treatment interruptions reported. Additionally, 13% of patients receiving...